Drug Profile
LTI 01
Alternative Names: LTI-01Latest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator Lung Therapeutics; University of Texas at Tyler
- Developer Aileron Therapeutics; University of Texas at Tyler
- Class Antibacterials; Antifibrotics; Plasminogen activator enzymes; Thrombolytics
- Mechanism of Action Fibrinolytic agents; Plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pleural effusion
- Phase I Empyema
Most Recent Events
- 01 Feb 2024 Phase-I development in Empyema and Pleural effusion in Australia and New Zealand (Intrapleural, Injection)
- 31 Oct 2023 Lung Therapeutics has been acquired and merged into Aileron Therapeutics
- 28 Sep 2022 Phase II development for Pleural effusion is ongoing in USA (NCT04159831) (Lung Therapeutics pipeline, September 2022)